Crossmark

Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature

Published Online: 2022-12-13

Authors

Chamorro, Yolcar https://orcid.org/0000-0002-1797-2960
Sandoval-Leon, Ana C.

Vogel, Charles L.

Nguyen, Michaela T.

Wang, Grace
License Information

Text and Data Mining valid from 2022-12-13

Version of Record valid from 2022-12-13
More Information

Article History

Received: 31 March 2022

Accepted: 16 November 2022

First Online: 13 December 2022

Declarations

:

: Not applicable.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: YC declares no competing interest. ACSL declares consulting/advisory relationship with Merck; research funding from OBI Pharma, Seattle Genetics, and Novartis. CLV declares consulting/advisory relationship and honoraria with Veru, Biotheranostics, and Novartis. MTN declares no competing interest. GW declares research funding from Eisai, Daiichi Sankyo Inc, Immunomedics Inc, Genentech Inc, Pfizer Inc, Pharmacyclics LLC, and Eli Lilly and Company.

Document is current